Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12879228 | 0.81 | LMNA (0.43) | — | |
| SCHEMBL12861004 | 0.81 | CHRM2 (0.33) | SMN1; SMN2 | |
| SCHEMBL413824 | 0.73 | NOTUM (0.41) | — | |
| SCHEMBL140205 | 0.73 | ALDH1A1 (0.40) | SMN1; SMN2 | |
| SCHEMBL13003306 | 0.72 | SMN1; SMN2 (0.42) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL659109 | 0.71 | ALDH1A1 (0.43) | SMN1; SMN2 | |
| SCHEMBL13534637 | 0.71 | SMN1; SMN2 (0.31) | SMN1; SMN2 | |
| SCHEMBL12879227 | 0.71 | MAPT (0.30) | SMN1; SMN2 | |
| SCHEMBL14456848 | 0.71 | CHRNB2 (0.65) | SMN1; SMN2 | |
| SCHEMBL6726839 | 0.70 | GPR119 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7652024-B2 | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20090325990-A1 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-12-31 | — | — | US | disclosed |
| US-7329673-B2 | Acylated spiropiperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2008-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325990-A1 | ACYLATED SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | MC4R, MC5R, MC3R | SMN1; SMN2 2085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.